Meeting
2021 ASCO Annual Meeting
Combination of sintilimab, anlotinib and pegaspargase "sandwich" with radiotherapy in localized natural killer/T cell lymphoma: A multicenter, phase 2 study.
Authors
Zhiming Li
Sun Yat-sen University Cancer Center, Guangzhou, China
Zhiming Li , Peng Sun , Yu Wang , Hang Yang , Yajun Li , Hui Zhou , Haiyan Yang , Liqun Zou
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT03936452
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 7537)
DOI
10.1200/JCO.2021.39.15_suppl.7537
Abstract #
7537
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A phase II study of anlotinib combined with STUPP regimen in the treatment of patients with newly diagnosed glioblastoma (GBM).
First Author: Peijing Li
Poster
2023 ASCO Annual Meeting
A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair–proficient (MMR-P) recurrent or persistent endometrial cancer (EC).
First Author: Elizabeth Katherine Lee
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Updated results from the phase II study: Efficacy and safety of anlotinib plus sintilimab as second-line treatment for patients with advanced biliary tract cancers.
First Author: Shuiling Jin
Poster
2018 ASCO Annual Meeting
A phase II trial of bevacizumab-GemAOD regimen for newly diagnosed extranodal NK/T cell lymphoma.
First Author: Zhiming Li